3:45 PMAbstract No. 8 - SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC)

F Moeslein,V Heinemann,N Sharma,M Findlay,J Ricke,R Dowling,D Price,V Gebski,M Van Buskirk,P Gibbs,G Van Hazel

doi:10.1016/j.jvir.2015.12.034

3:45 PMAbstract No. 8 - SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC)

F Moeslein, V Heinemann + Show 9 more

https://doi.org/10.1016/j.jvir.2015.12.034

Copy DOI

Journal: Journal of Vascular and Interventional Radiology

Publication Date: Mar 1, 2016

Affiliation: University of Maryland Medical Center, Ludwig-Maximilians-Universität München, University of Maryland, Baltimore, Clinical Trials New Zealand, University Hospital Magdeburg, Royal Melbourne Hospital, Mount Medical Centre, Cooperative Trials Group for Neuro-Oncology, National Health and Medical Research Council, University of Western Australia

#Site Of First Progression #Selective Internal Radiation Therapy + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

3:45 PMAbstract No. 8 - SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Vascular and Interventional Radiology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.